Medical/Pharmaceuticals
Experts attending P&G Health's Global Webinar Series highlight underdiagnosis concerns as Peripheral Neuropathy becomes more prevalent
- Often underestimated and diagnosed late, increasing awareness and early-stage screening of Peripheral Neuropathy by primary care physicians can help prevent long-term complications and quality of life restrictions. - The Global Webinar Series for healthcare professionals has 'Virtual Pavilions...
2022-05-30 16:12
2262
RhoVac's phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint
STOCKHOLM, May 30, 2022 /PRNewswire/ -- RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, regrets to announce today onMay 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 (on...
2022-05-30 11:04
1623
United BioPharma Receives TFDA Approval for Phase 2 IND for UB-221 to Treat Chronic Spontaneous Urticaria
TAIPEI, May 30, 2022 /PRNewswire/ -- Taiwan-based United BioPharma (UBP) has
announced the approval of a Phase 2 clinical trial with novel anti-IgE
monoclonal antibody UB-221 by the Taiwan Food and Drug Administration (TFDA).
2022-05-30 10:59
1661
InxMed IN10018 at ASCO 2022 demonstrates robust efficacy in patients with platinum-resistant recurrent ovarian cancer
NANJING, China, May 29, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting stroma microenvironment and drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label...
2022-05-30 08:10
1653
Illuccix® Reimbursement Milestone and Launch Updates: Pass-Through Status Granted in the U.S.
MELBOURNE, Australia and INDIANAPOLIS, May 30, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on the U.S. and Australian launch and reimbursement status for its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium (68...
2022-05-30 08:02
2579
MedAlliance's SELUTION SLR drug-eluting balloon (DEB) receives FDA investigational device exemption (IDE) approval, making it the first limus DEB to be available to US patients
GENEVA, May 30, 2022 /PRNewswire/ -- The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained drug release, similar to a drug-eluting stent (DES). SELUTION SLR was also the first DEB (Drug Eluting Balloon) granted "breakthrough device de...
2022-05-30 08:00
2083
IASO Biotherapeutics' Equecabtagene Autoleucel, the World's First CAR-T for Treatment of NMOSD, Receives IND Application Acceptance by NMPA
SAN JOSE, Calif., NANJING, China and SHANGHAI, May 28, 2022 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative cell therapies and antibody products, announced today thatChina's National Medic...
2022-05-28 19:33
4960
Jacobio will Present Phase I Clinical Data of KRAS G12C Inhibitor JAB-21822 at the 2022 ASCO Annual Meeting
BEIJING, SHANGHAI and BOSTON, May 27, 2022 /PRNewswire/ -- Jacobio Pharma (1167.HK) is pleased to announce that the phase I clinical data of KRAS G12C inhibitor JAB-21822 will be presented in the form of poster at the upcoming 2022 annual meeting of American Society of Clinical Oncology (ASCO) fr...
2022-05-28 00:22
5973
Asieris to present a study protocol of APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy（NAC）for muscle invasive bladder cancer (MIBC) patients at 2022 ASCO annual meeting
SHANGHAI, May 27, 2022 /PRNewswire/ -- Asieris Pharmaceuticals (688176.SH), a global innovative biopharma company specializing in discovering and developing innovative drugs for the treatment of genitourinary tumors and other major diseases announced that ANTICIPATE Study will be presented at the...
2022-05-27 22:16
2775
ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017
SHANGHAI, May 27, 2022 /PRNewswire/ -- OriCell Therapeutics Co., Ltd (OriCell), a leading innovative biopharmaceutical company pioneering novel oncology cell therapies for the unmet medical needs in in hematology and oncology, today announced that an abstract detailing data from a Phase I study(P...
2022-05-27 21:49
2410
Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022
Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion mutations after platinum and anti-PD(L)1 treatment failures Golidocitinib (DZD4205) demonstrates enormous potential for peripheral T-cell lymphoma DZD1516 exemplifies full BBB-penetration in patie...
2022-05-27 18:00
1494
ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development
SUZHOU, China, and ROCKVILLE, Md., May 26, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its seven clinical abstracts selected by the ...
2022-05-27 10:02
2126
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels
- First clinical data demonstrating potential of SAFEbody technology platform to create best-in-class therapeutics - - Additional data from ongoing ADG126 clinical program to be presented in second half of 2022, including safety in combination with anti-PD-1 therapies - SAN DIEGO and SUZHOU, Chi...
2022-05-27 09:30
4882
New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment
* Lunit to showcase 7 poster presentations and 4 online publications, the company's largest publication set at ASCO to date * Findings demonstrate the practical effectiveness of Lunit's AI solutions in the pathological assessment of tumors across more than 16 primary cancer types SEOUL, South...
2022-05-27 08:30
1823
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
- Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity - Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort - Results indicate CD73 expression correlates with clini...
2022-05-27 05:01
2003
Portfolio Highlights: Clinical and Financing Updates of Anji, AIxplorerBio, Domain, VivaVision, ArrePath, QurAlis and Apeiron
SHANGHAI, May 26, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 month, our portfolio companies have had great progress. Anji Pharma Complete...
2022-05-26 23:53
2886
Menarini inaugurates new regional headquarters in Dubai, UAE
The pharmaceutical group, present in 140 countries in the world, aims to raise standard of patient healthcare across theMiddle East and Africa (MEA) region with innovative products and breakthrough research DUBAI, UAE, May 26, 2022 /PRNewswire/ -- Menarini, the leading Italian pharmaceutical gro...
2022-05-26 23:16
2912
Dr Neal Shore joins Clarity's Clinical Advisory Board
SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that DrNeal Shore has joined Clarity's Clinical Advisory Board (C...
2022-05-26 21:08
2026
US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD
Key Highlights: * US FDA has cleared Cynata's IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company * Phase 2 clinical study in aGvHD expected to commence subsequent to customary and satisfactory completion of ne...
2022-05-26 20:44
2122
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
SHANGHAI and WARREN, N.J., May 26, 2022 /PRNewswire/ -- Laekna Therapeutics, a clinical-stage biotechnology company developing innovative medicines to treat cancer and liver diseases, today announced that two first patients have been dosed in the U.S. andChina, respectively, in a Phase Ib/III cli...
2022-05-26 20:27
1524
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
[Picked up by 286 media titles]
2024-04-19 13:25
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Most Read
Combining Sustainability and Cybersecurity: Century Iron & Steel and Century Wind Power Both Receive ISO 27001 Information Security Certification
2024-04-19 18:03
9198
China's Yiwu Establishes Welcoming Committee to Attract International Buyers
2024-04-19 13:25
7771
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
5194
